Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating income | -$365K | -$4.24M |
| Net income | -$362K | -$4.23M |
| EPS (diluted) | -$0.03 | -$0.17 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$556K | -$10.5M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | — | $5.00M |
| Total assets | $518K | $11.6M |
| Total liabilities | $14.6K | $361K |
| Shareholders' equity | $503K | $11.2M |
| Retained earnings | -$622K | -$4.85M |
| Shares (wtd avg diluted) | 13.3M | 25.5M |
Every figure is extracted from Curanex Pharmaceuticals Inc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.